Top

Published in:

30-01-2025 | Neurological Therapy | Review

Vaccine Based Approaches for the Prevention and Treatment of Neurological Disease

Authors: Nicholas Aderinto, Israel Charles Abraham, Gbolahan Olatunji, Emmanuel Kokori, Patrick Ashinze, Emmanuel Adeoba Babawale, Badrudeen Olalekan Alabi, Olaewe David Opeyemi, Adetola Emmanuel Babalola, Ayoola Ikeoluwa Oluwapelumi, Chidinma Udojike, Okikiola Sobuur Fagbolade, Festus Oluseye Babarinde, Ololade Wiquoyat Oyesiji, Bonaventure Michael Ukoaka, Alexander Idu Entonu, Matthew Tolulope Olawoyin, Olayinka Fakorede

Published in: Current Treatment Options in Neurology | Issue 1/2025

Abstract

Purpose of Review

This review examines the potential of vaccine-based strategies in preventing and modifying the progression of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis, and Creutzfeldt-Jakob Disease. It explores the pathophysiology of these diseases and highlights the challenges in developing effective vaccines, such as crossing the blood–brain barrier and achieving precise immune modulation.

Recent Findings

Advances in vaccine technologies, including messenger RNA (mRNA) platforms, novel delivery systems, plant-based vaccines, and gene-editing approaches, have shown promise in enhancing immunogenicity and specificity. These innovations address key obstacles in targeting neurodegenerative pathologies and present opportunities for preventive and therapeutic interventions. Ethical considerations and public health implications further show the importance of interdisciplinary research efforts.

Summary

Vaccine-based strategies hold significant promise in addressing the unmet needs of neurodegenerative disease prevention and treatment. However, translating these advancements into clinical applications requires sustained research, robust clinical trials, and a focus on ethical and regulatory frameworks. Interdisciplinary collaboration is critical to accelerate progress and improve outcomes for patients at risk of or affected by neurodegenerative disorders.

Thakur KT, Albanese E, Giannakopoulos P, et al. Neurological disorders. In: Patel V, Chisholm D, Dua T, et al., editors. Mental, neurological, and substance use disorders: disease control priorities, 3rd ed (vol 4). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016. Chapter 5. Available from: https://doi.org/10.1596/978-1-4648-0426-7_ch5

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Steinmetz, Jaimie D et al. The Lancet Neurol. 23(4):344-381. https://doi.org/10.1016/S1474-4422(24)00038-3

Farooqui T, Farooqui AA. Perspective and directions for future research on trace amines and neurological disorders. In: Elsevier eBooks [Internet]. 2016. p. 369–86. Available from: https://www.sciencedirect.com/topics/neuroscience/neurological-disorder. Accessed 2 Oct 2024.

Mesulam M M. Aphasia: sudden and progressive☆. In: Elsevier eBooks [Internet]. 2016. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/degenerative-disease. Accessed 2 Oct 2024.

Farooqui AA. Neurochemical aspects of neurotraumatic and neurodegenerative diseases. New York: Springer; 2010.CrossRef

Ma K, Yu J, Shao W, Xu X, Zhang Z, Zhang D. Functional overlaps exist in neurological and psychiatric disorders: a proof from brain network analysis. Neuroscience. 2020;15(425):39–48. https://doi.org/10.1016/j.neuroscience.2019.11.018.CrossRef

The Lancet Neurology. Improving access to medicines for neurological disorders. Lancet Neurol. 2024;23(10):951. https://doi.org/10.1016/S1474-4422(24)00371-5.CrossRefPubMed

Hu Y, Hu K, Song H, Pawitan Y, Piehl F, Fang F. Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease. Brain Commun. 2023;5(2):065. https://doi.org/10.1093/braincomms/fcad065.CrossRef

Feigin VL, Vos T, Nichols E, Owolabi MO, Carroll WM, Dichgans M, Deuschl G, Parmar P, Brainin M, Murray C. The global burden of neurological disorders: translating evidence into policy. The Lancet Neurol. 2020;19(3):255–65. https://doi.org/10.1016/S1474-4422(19)30411-9.CrossRefPubMed

10.

Riedel S. Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University. Medical Center). 2005;18(1):21–25. https://doi.org/10.1080/08998280.2005.11928028

11.

Orsini D, Valchi L, Minet C, Martini M. The history of polio vaccination with “Sabin’s OPV” 60 years after its introduction in Italy: an unforgivable “delay.” J Prev Med Hyg. 2024;65(1):105–12. https://doi.org/10.15167/2421-4248/jpmh2024.65.1.3242.CrossRef

12.

Simonsen KA, Snowden J. Smallpox. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470418/. Accessed 2 Oct 2024.

13.

Miller MA, Sentz JT. Vaccine-Preventable Diseases. In: Jamison DT, Feachem RG, Makgoba MW, et al., editors. Disease and mortality in Sub-Saharan Africa. 2nd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2006. Chapter 12. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2284/. Accessed 2 Oct 2024.

14.

Chumakov K, Avidan MS, Benn CS, Bertozzi SM, Blatt L, Chang AY, Jamison DT, Khader SA, Kottilil S, Netea MG, Sparrow A, Gallo RC. Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci USA. 2021;118(21):e2101718118. https://doi.org/10.1073/pnas.2101718118.CrossRefPubMedPubMedCentral

15.

Vaccine types. NIAID: National Institute of Allergy and Infectious Diseases. 2019. Available from: https://www.niaid.nih.gov/research/vaccine-types. Accessed 2 Oct 2024.

16.

Bravo-Vázquez LA, Mora-Hernández EO, Rodríguez AL, Sahare P, Bandyopadhyay A, Duttaroy AK, Paul S. Current advances of plant-based vaccines for neurodegenerative diseases. Pharmaceutics. 2023;15(2):711. https://doi.org/10.3390/pharmaceutics15020711.CrossRefPubMedPubMedCentral

17.

Ciurea AV, Mohan AG, Covache-Busuioc R-A, Costin H-P, Glavan L-A, Corlatescu A-D, Saceleanu VM. Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer’s, parkinson’s, and huntington’s diseases and amyotrophic lateral sclerosis. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241310809.CrossRefPubMedPubMedCentral

18.

Eva L, Pleș H, Covache-Busuioc R-A, Glavan LA, Bratu B-G, Bordeianu A, Dumitrascu D-I, Corlatescu AD, Ciurea AV. A comprehensive review on neuroimmunology: insights from multiple sclerosis to future therapeutic developments. Biomedicines. 2023. https://doi.org/10.3390/biomedicines11092489.CrossRefPubMedPubMedCentral

19.

Strafella C, Caputo V, Galota MR, Zampatti S, Marella G, Mauriello S, Cascella R, Giardina E. Application of precision medicine in neurodegenerative diseases. Front Neurol. 2018;9:701.PubMedPubMedCentralCrossRef

20.

Vassilakopoulou V, Karachaliou C-E, Evangelou A, Zikos C, Livaniou E. Peptide-based vaccines for neurodegenerative diseases: recent endeavors and future perspectives. Vaccines. 2021. https://doi.org/10.3390/vaccines9111278.CrossRefPubMedPubMedCentral

21.

DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14:32.PubMedPubMedCentralCrossRef

22.

Wu T, Lin D, Cheng Y, Jiang S, Riaz MW, Fu N, Mou C, Ye M, Zheng Y. Amyloid cascade hypothesis for the treatment of Alzheimer’s disease: progress and challenges. Aging Dis. 2022;13:1745–58.PubMedPubMedCentralCrossRef

23.

Kwan P, Konno H, Chan KY, Baum L. Rationale for the development of an Alzheimer’s disease vaccine. Hum Vaccin Immunother. 2020;16:645–53.PubMedCrossRef

24.

Mantile F, Prisco A. Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease. Biology (Basel). 2020. https://doi.org/10.3390/biology9120425.CrossRefPubMed

25.

Oberman K, Gouweleeuw L, Hoogerhout P, Eisel ULM, van Riet E, Schoemaker RG. Vaccination prevented short-term memory loss, but deteriorated long-term spatial memory in Alzheimer’s disease mice, independent of amyloid-β pathology. J Alzheimer’s Dis Rep. 2020;4:261–80.CrossRef

26.

Sun Y, Guo Y, Feng X, Fu L, Zheng Y, Dong Y, Zhang Y, Yu X, Kong W, Wu H. Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer’s disease. Signal Transduct Target Ther. 2021;6:61.PubMedPubMedCentralCrossRef

27.

Davtyan H, Hovakimyan A, Kiani Shabestari S, et al. Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice. Alzheimers Res Ther. 2019;11:107.PubMedPubMedCentralCrossRef

28.

Meissner WG, Traon AP-L, Foubert-Samier A, et al. A phase 1 randomized trial of specific active α-synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord. 2020;35:1957–65.PubMedPubMedCentralCrossRef

29.

Novak P, Schmidt R, Kontsekova E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:108.PubMedPubMedCentralCrossRef

30.

V. Vassilakopoulou Chrysoula-Evangelia Karachaliou AECZEL. Peptide-based vaccines for neurodegenerative diseases: recent endeavors and future perspectives. Vaccines. 2021;. https://doi.org/10.3390/vaccines9111278

31.

Wojtunik-Kulesza K, Rudkowska M, Orzeł-Sajdłowska A. Aducanumab-hope or disappointment for Alzheimer’s disease. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24054367.CrossRefPubMedPubMedCentral

32.

Das R, Blázquez-Gamero D, Bernstein DI, et al. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Infect Dis. 2023;23:1383–94.PubMedCrossRef

33.

Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16:123–34.PubMedCrossRef

34.

Vashishtha VM, Kumar P. The durability of vaccine-induced protection: an overview. Expert Rev Vaccines. 2024;23:389–408.PubMedCrossRef

35.

Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2018;36(36):5350–7. https://doi.org/10.1016/j.vaccine.2017.07.062.CrossRefPubMed

36.

Poland GA, Ovsyannikova IG, Kennedy RB, Lambert ND, Kirkland JL. A systems biology approach to the effect of aging, immunosenescence and vaccine response. Curr Opin Immunol. 2014;9(29C):62–8.CrossRef

37.

Castiblanco J, Anaya JM. Genetics and vaccines in the era of personalized medicine. Curr Genom. 2015;16(1):47–59.CrossRef

38.

Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, Gunthard HF, et al. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut. 2014;64(5):813–9.PubMedCrossRef

39.

Jarduli LR, Sell AM, Reis PG, Sippert EA, Ayo CM, Mazini PS, et al. Role of HLA, KIR, MICA, and cytokines genes in leprosy. Biomed Res Int. 2013;2013:989837.PubMedPubMedCentralCrossRef

40.

Ali S, Chopra R, Aggarwal S, Srivastava AK, Kalaiarasan P, Malhotra D, et al. Association of variants in BAT1-LTA-TNF-BTNL2 genes within 6p21.3 region show graded risk to leprosy in unrelated cohorts of Indian population. Human Genet. 2012;131(5):703–16.CrossRef

41.

Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev. 2013;254(1):245–64.PubMedPubMedCentralCrossRef

42.

Ovsyannikova IG, Haralambieva IH, Vierkant RA, O’Byrne MM, Jacobson RM, Poland GA. The association of CD46, SLAM, and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses–a replication study and examination of novel polymorphisms. Human Hered. 2011;72(3):206–23.CrossRef

43.

Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338–49.PubMedPubMedCentralCrossRef

44.

Klein SL, Poland GA. Personalized vaccinology: one size and dose might not fitboth sexes. Vaccine. 2013;31(23):2599–600.PubMedCrossRef

45.

Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985;254(22):3187–9.PubMedCrossRef

46.

Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody titers in overweight children. Autoimmunity. 2006;39(2):137–41.PubMedPubMedCentralCrossRef

47.

Talbot HK, Coleman LA, Crimin K, Zhu Y, Rock MT, Meece J, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine. 2012;30(26):3937–43.PubMedPubMedCentralCrossRef

48.

Karlsson EA, Sheridan PA, Beck MA. Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol. 2010;184(6):3127–33.PubMedCrossRef

49.

Hirtz D, et al. How common are the ‘common’ neurologic disorders? Neurology. 2007;68:326–37.PubMedCrossRef

50.

Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. Drug Discov Today. 2018;23(5):1007–15. https://doi.org/10.1016/j.drudis.2017.11.010.CrossRefPubMed

51.

Jain, KK. Role of nanobiotechnology in the development of personalized medicine. Journal. 2009. https://doi.org/10.2217/nnm.09.12

52.

Vizirianakis IS. Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine. 2011;7:11–7.PubMedCrossRef

53.

Kaushik A, et al. The potential of magneto-electric nanocarriers for drug delivery. Expert Opin Drug Deliv. 2014;11:1635–46.PubMedPubMedCentralCrossRef

54.

Ruiz A, et al. Recent update in NanoCure of NeuroAIDS. Sci Lett J. 2015;4:172.

55.

Yang Z, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine. 2010;6:427–41.PubMedCrossRef

56.

Mathew A, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS ONE. 2012;7: e32616.PubMedPubMedCentralCrossRef

57.

Lee HJ, et al. Amine-modified single-walled carbon nanotubes protect neurons from injury in a rat stroke model. Nat Nanotechnol. 2011;6:121–5.PubMedPubMedCentralCrossRef

58.

Moon SU, et al. Carbon nanotubes impregnated with subventricular zone neural progenitor cells promotes recovery from stroke. Int J Nanomedicine. 2012;7:2751.PubMedPubMedCentral

59.

Lambracht-Washington D, Rosenberg RN. Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease. ImmunoTargets Ther. 2013;2:105–14. https://doi.org/10.2147/ITT.S31428.CrossRefPubMedCentral

60.

Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alz Res Ther. 2014;6:44. https://doi.org/10.1186/alzrt278.CrossRef

61.

Park JS, Choe RAK, et al. Immunization effects of a novel alpha synuclein based peptide in Parkinson disease-associated pathology. MDPI J. 2023. Available at https://www.mdpi.com/2076-393X/11/12/1820. Accessed 2 Oct 2024.

62.

Fariha Jamal MD. Immunotherapies targeting alpha synuclein in Parkinson disease. 2020. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473734/. Accessed 2 Oct 2024.

63.

Correale J, Farez M, Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs. 2008;22:175–98.PubMedCrossRef

64.

Wilson DB, Golding AB, Smith RA, Dafashy T, Nelson J, Smith L, Carlo DJ, Brostoff SW, Gold DP. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J Neuroimmunol. 1997;76(1–2):15–28.PubMedCrossRef

65.

Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9–23) peptide. Diabetes. 2002;51(7):2126–34.PubMedCrossRef

66.

Sloan-Lancaster J, Allen PM. Altered peptide ligand–induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol. 1996;14(1):1–27.PubMedCrossRef

67.

Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther. 2011;11(7):961–7.PubMedCrossRef

68.

Reindl M, Khantane S, Ehling R, Schanda K, Lutterotti A, Brinkhoff C, Oertle T, Schwab ME, Deisenhammer F, Berger T, Bandtlow CE. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J Neuroimmunol. 2003;145(1–2):139–47.PubMedCrossRef

69.

Fontoura P, Ho PP, DeVoss J, Zheng B, Lee BJ, Kidd BA, Garren H, Sobel RA, Robinson WH, Tessier-Lavigne M, Steinman L. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol. 2004;173(11):6981–92.PubMedCrossRef

70.

Hafler DA, Cohen I, Benjamin DS, Weiner HL. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol. 1992;62(3):307–13.PubMedCrossRef

71.

Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, Smith L, Diveley J, Laxer JA, Richieri SP, Carlo DJ. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis II Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. J Neuroimmunol. 1997;76(1–2):29–38.PubMedCrossRef

72.

Zang YC, Hong J, Rivera VM, Killian J, Zhang JZ. Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol. 2000;164(8):4011–7.PubMedCrossRef

73.

Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol. 2006;64(3):205–10.PubMedCrossRef

74.

Hermans G, Denzer U, Lohse A, Raus J, Stinissen P. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination. J Autoimmun. 1999;13(2):233–46.PubMedCrossRef

75.

Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with Tlymphocite line cells reactive against myelin basic protein. Nature. 1981;292(5818):60–1.PubMedCrossRef

76.

Ramsingh AI, Manley K, Rong Y, Reilly A, Messer A. Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington′s disease. Hum Mol Genet. 2015;24:6186–97. https://doi.org/10.1093/hmg/ddv335.CrossRefPubMedPubMedCentral

77.

Fatoba O, Ohtake Y, Itokazu T, Yamashita T. Immunotherapies in Huntington’s disease and α-Synucleinopathies. Front Immunol. 2020;11:337. https://doi.org/10.3389/fimmu.2020.00337.CrossRefPubMedPubMedCentral

78.

Armon C. Amyotrophic lateral sclerosis. Medscape. 2024. Available from: https://emedicine.medscape.com/article/1170097-overview?form=fpf. Accessed 2 Oct 2024.

79.

Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull. 2016;119(1):87–98. https://doi.org/10.1093/bmb/ldw026.CrossRefPubMed

80.

Jo M, Lee S, Jeon YM, et al. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52:1652–62. https://doi.org/10.1038/s12276-020-00513-7.CrossRefPubMedPubMedCentral

81.

Riemenschneider H, Simonetti F, Sheth U, et al. Targeting the glycine-rich domain of TDP-43 with antibodies prevents its aggregation in vitro and reduces neurofilament levels in vivo. Acta Neuropathol Commun. 2023;11:112. https://doi.org/10.1186/s40478-023-01592-z.CrossRefPubMedPubMedCentral

82.

Audrain M, et al. Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 species in cerebrospinal fluid. Brain Commun. 2023;5(6):fcad306.PubMedPubMedCentralCrossRef

83.

Zhao B, Marciniuk K, Gibbs E, Yousefi M, Napper S, Cashman NR. Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. Vaccine. 2019;37(35):4920–7. https://doi.org/10.1016/j.vaccine.2019.07.044.CrossRefPubMed

84.

Lin TJ, Cheng GC, Wu LY, Lai WY, Ling TY, Kuo YC, Huang YH. Potential of cellular therapy for ALS: current strategies and future prospects. Front Cell Dev Biol. 2022;16(10):851613. https://doi.org/10.3389/fcell.2022.851613. (Erratum in: Front Cell Dev Biol. 2023 Sep 19;11:1292681. 10.3389/fcell.2023.1292681).CrossRef

85.

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012(3):CD001447. https://doi.org/10.1002/14651858.CD001447.pub3.CrossRefPubMedPubMedCentral

86.

Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919–30. https://doi.org/10.1056/NEJMoa1916945.CrossRefPubMedPubMedCentral

87.

U.S. Food and Drug Administration. FDA approves Relyvrio for treatment of ALS [Internet]. 2022 [cited 2024 Sep 27]. Available from: https://www.fda.gov. Accessed 2 Oct 2024.

88.

Mora JS, Genge A, Chio A, et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1–2):5–14. https://doi.org/10.1080/21678421.2019.1632346. (Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):223. 10.1080/21678421.2023.2273111.).CrossRefPubMed

89.

Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5(1):64–79. https://doi.org/10.1002/emmm.201201544. (Erratum in: EMBO Mol Med. 2013 Feb;5(2):326.).CrossRefPubMed

90.

Rothstein JD. Excitotoxicity hypothesis. Neurology. 1996;47(4 Suppl 2):S19-25. https://doi.org/10.1212/wnl.47.4_suppl_2.19s.CrossRefPubMed

91.

Beers DR, Henkel JS, Zhao W, Wang J, Huang A, Wen S, Liao B, Appel SH. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain. 2011;134(Pt 5):1293–314. https://doi.org/10.1093/brain/awr074.CrossRefPubMedPubMedCentral

92.

Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012;237(1):147–52. https://doi.org/10.1016/j.expneurol.2012.06.011.CrossRefPubMedPubMedCentral

93.

Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007;6(12):1045–53. https://doi.org/10.1016/S1474-4422(07)70270-3.CrossRefPubMed

94.

Philips T, Rothstein JD. Glial cells in amyotrophic lateral sclerosis. Exp Neurol. 2014;262:111–20. https://doi.org/10.1016/j.expneurol.2014.05.015.CrossRefPubMed

95.

Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251–3. https://doi.org/10.1038/nn2047.CrossRefPubMedPubMedCentral

96.

Crane MA, Nair-Desai S, Gemmill A, Romley JA, Probasco JC. Change in epidemiology of creutzfeldt-jakob disease in the US, 2007–2020. JAMA Neurol. 2024;81(2):195–7. https://doi.org/10.1001/jamaneurol.2023.4678.CrossRefPubMed

97.

Wisniewski T, Goñi F. Vaccination strategies. Handb Clin Neurol. 2017;153:419–430, https://doi.org/10.1016/B978-0-444-63945-5.00023-4. Accessed 2 Oct 2024

98.

Liu F, et al. New implications for prion diseases therapy and prophylaxis. Front Mol Neurosci. 2024;17:1324702. https://doi.org/10.3389/fnmol.2024.1324702. Accessed 2 Oct. 2024.

99.

Nicoll AJ, Trevitt CR, Tattum MH, Risse E, Quarterman E, Ibarra AA, et al. Pharmacological chaperone for the structured domain of human prion protein. Proc Natl Acad Sci USA. 2010;107:17610–5. https://doi.org/10.1073/pnas.1009062107.CrossRefPubMedPubMedCentral

100.

Ishibashi D, Yamanaka H, Yamaguchi N, Yoshikawa D, Nakamura R, Okimura N, et al. Immunization with recombinant bovine but not mouse prion protein delays the onset of disease in mice inoculated with a mouse-adapted prion. Vaccine. 2007;25:985–92. https://doi.org/10.1016/j.vaccine.2006.09.078.CrossRefPubMed

101.

Sigurdsson EM, Brown DR, Daniels M, Kascsak RJ, Kascsak R, Carp R, et al. Immunization delays the onset of prion disease in mice. Am J Pathol. 2002;161:13–7. https://doi.org/10.1016/S0002-9440(10)64151-X.CrossRefPubMedPubMedCentral

102.

Taschuk R, Scruten E, Woodbury M, Cashman N, Potter A, Griebel P, et al. Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease. Prion. 2017;11:368–80. https://doi.org/10.1080/19336896.2017.1367083.CrossRefPubMedPubMedCentral

103.

Ma Y, Ma J. Immunotherapy against prion disease. Pathogens. 2020;9:219. https://doi.org/10.3390/pathogens9030216.CrossRef

104.

Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G, DeArmond SJ, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog. 2009;5:e1000673. https://doi.org/10.1371/journal.ppat.1000673.CrossRefPubMedPubMedCentral

105.

Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539:217–26. https://doi.org/10.1038/nature20415.CrossRefPubMed

106.

Zang X. 2018. Nobel Prize in medicine awarded to cancer immunotherapy: Immune checkpoint blockade - a personal account. Genes Dis. 2018;5:302–3. https://doi.org/10.1016/j.gendis.2018.10.003.CrossRefPubMedPubMedCentral

107.

Chakraborty C, Bhattacharya NM, Dhama K. SARS-CoV-2 vaccines, vaccine development technologies, and significant efforts in vaccine development during the pandemic: the lessons learned might help to fight against the next pandemic. Vaccines. 2023;11(3):682. https://doi.org/10.3390/vaccines11030682.CrossRefPubMedPubMedCentral

108.

Wu T-T, Qian J, Ang J, Sun R. Challenges to herpesvirus vaccine development. https://www.sciencedirect.com/topics/medicine-and-dentistry/herpes-vaccine#:~:text=Major%20challenges%20to%20vaccine%20development,genes%20encoded%20by%20the%20viruses. Accessed 2 Oct 2024.

109.

Kollias CM, Huneke RB, Wigdahl B, et al. Animal models of herpes simplex virus immunity and pathogenesis. J Neurovirol. 2015;21:8–23. https://doi.org/10.1007/s13365-014-0302-2.CrossRefPubMed

110.

Badizadegan K, Kalkowska DA, Thompson KM. Polio by the numbers-a global perspective. J Infect Dis. 2022;226(8):1309–18. https://doi.org/10.1093/infdis/jiac130.CrossRefPubMedPubMedCentral

111.

Geiger K, Stehling-Ariza T, Bigouette JP, Bennett SD, Burns CC, Quddus A, Wassilak SGF, Bolu O. Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023. MMWR Morb Mortal Wkly Rep. 2024;73(19):441–446. https://doi.org/10.15585/mmwr.mm7319a4

112.

Rana MS, et al. The resurgence of wild poliovirus in Pakistan and Afghanistan: A new setback for polio eradication. https://doi.org/10.1016/j.jinf.2022.05.038

113.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652–61. https://doi.org/10.1056/NEJMoa011915.CrossRefPubMed

114.

Belshe RB, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43. https://doi.org/10.1056/NEJMoa110315.CrossRefPubMedPubMedCentral

115.

Moutschen M, Léonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine. 2007;25(24):4697–705. https://doi.org/10.1016/j.vaccine.2007.04.008.CrossRefPubMed

116.

ModernaTX, Inc. A study of an Epstein-Barr Virus (EBV) candidate vaccine, mRNA-1189, in 10- to 30-year-old healthy adolescents and adults [Internet]. ClinicalTrials.gov Identifier: NCT05164094. Updated 2025 Jan 8. Available from: https://clinicaltrials.gov/ct2/show/NCT05164094

117.

National Institute of Allergy and Infectious Diseases (NIAID). Safety and immunogenicity of an Epstein-Barr Virus (EBV) gp350-ferritin nanoparticle vaccine in healthy adults with or without EBV infection [Internet]. ClinicalTrials.gov Identifier: NCT04645147. Available from: https://clinicaltrials.gov/ct2/show/NCT0464514

118.

Turk SM, Jiang R, Chesnokova LS, Hutt-Fletcher LM. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J Virol. 2006;80(19):9628–33. https://doi.org/10.1128/JVI.00622-06.CrossRefPubMedPubMedCentral

119.

Chesnokova LS, Hutt-Fletcher LM. Fusion of Epstein-Barr virus with epithelial cells can be triggered by αvβ5 in addition to αvβ6 and αvβ8, and integrin binding triggers a conformational change in glycoproteins gHgL. J Virol. 2011;85(24):13214–23. https://doi.org/10.1128/JVI.05580-11.CrossRefPubMedPubMedCentral

120.

Brooks JM, Long HM, Tierney RJ, Shannon-Lowe C, Leese AM, Fitzpatrick M, Taylor GS, Rickinson AB. Early T cell recognition of b cells following epstein-barr virus infection: identifying potential targets for prophylactic vaccination. PLoS Pathog. 2016;12(4):e1005549. https://doi.org/10.1371/journal.ppat.1005549.CrossRefPubMedPubMedCentral

121.

Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003;18(5):593–603. https://doi.org/10.1016/s1074-7613(03)00112-2.CrossRefPubMedPubMedCentral

122.

Khanna KM, Lepisto AJ, Decman V, Hendricks RL. Immune control of herpes simplex virus during latency. Curr Opin Immunol. 2004;16(4):463–9. https://doi.org/10.1016/j.coi.2004.05.003.CrossRefPubMed

123.

Odegard JM et al. Novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. https://doi.org/10.1016/j.vaccine.2015.10.137.

124.

Zhang W, Xiao D, Mao Q, et al. Role of neuroinflammation in neurodegeneration development. Sig Transduct Target Ther. 2023;8:267. https://doi.org/10.1038/s41392-023-01486-5.CrossRef

125.

Doty KR, Guillot-Sestier MV, Town T. The role of the immune system in neurodegenerative disorders: adaptive or maladaptive? Brain Res. 2015;1617:155–73. https://doi.org/10.1016/j.brainres.2014.09.008.CrossRefPubMed

126.

Lehrer S, Rheinstein PH. Vaccination reduces risk of Alzheimer’s Disease, Parkinson’s disease and other neurodegenerative disorders. Discov Med. 2022;34(172):97–101.PubMedPubMedCentral

127.

Kennedy RB, Ovsyannikova IG, Palese P, Poland GA. Current challenges in vaccinology. Front Immunol. 2020;11:1181. https://doi.org/10.3389/fimmu.2020.01181. (Published 2020 Jun 25).CrossRefPubMedPubMedCentral

128.

Iqbal SM, Rosen AM, Edwards D, Bolio A, Larson HJ, Servin M, Rudowitz M, Carfi A, Ceddia F. Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19. Front Public Health. 2024;8(12):1429265.CrossRef

129.

Wang YS, Kumari M, Chen GH, et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. J Biomed Sci. 2023;30:84. https://doi.org/10.1186/s12929-023-00977-5.CrossRefPubMedPubMedCentral

130.

Kheirollahpour M, Mehrabi M, Dounighi NM, Mohammadi M, Masoudi A. Nanoparticles and vaccine development. Pharm Nanotechnol. 2020;8(1):6–21.PubMedCrossRef

131.

132.

Rahimian N, Miraei HR, Amiri A, Ebrahimi MS, Nahand JS, Tarrahimofrad H, Hamblin MR, Khan H, Mirzaei H. Plant-based vaccines and cancer therapy: where are we now and where are we going? Pharmacol Res. 2021;169:105655. https://doi.org/10.1016/j.phrs.2021.105655.CrossRefPubMed

133.

LeBlanc Z, Waterhouse P, Bally J. Plant-based vaccines: the way ahead? Viruses. 2021;13:5. https://doi.org/10.3390/v13010005.CrossRef

134.

Dhama K, Natesan S, Iqbal YM, Patel SK, Tiwari R, Saxena SK, Harapan H. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects. Hum Vaccines Immunother. 2020;16:2913–20. https://doi.org/10.1080/21645515.2020.1842034.CrossRef

135.

Bhujbal S, Bhujbal R, Giram P. An overview: CRISPR/Cas-based gene editing for viral vaccine development. Expert Rev Vaccines. 2022;21(11):1581–93.PubMedCrossRef

Title: Vaccine Based Approaches for the Prevention and Treatment of Neurological Disease
Authors: Nicholas Aderinto
Israel Charles Abraham
Gbolahan Olatunji
Emmanuel Kokori
Patrick Ashinze
Emmanuel Adeoba Babawale
Badrudeen Olalekan Alabi
Olaewe David Opeyemi
Adetola Emmanuel Babalola
Ayoola Ikeoluwa Oluwapelumi
Chidinma Udojike
Okikiola Sobuur Fagbolade
Festus Oluseye Babarinde
Ololade Wiquoyat Oyesiji
Bonaventure Michael Ukoaka
Alexander Idu Entonu
Matthew Tolulope Olawoyin
Olayinka Fakorede
Publication date: 30-01-2025
Publisher: Springer US
Keywords: Neurological Therapy
Vaccination in the General Practice
Vaccination in Old Age
Alzheimer Disease
Parkinson Disease
Multiple Sclerosis
Huntington Disease
Amyotrophic Lateral Sclerosis
Creutzfeldt-Jakob Disease
Alzheimer's Disease
Published in: Current Treatment Options in Neurology / Issue 1/2025
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-025-00827-9

Tau in Multiple Sclerosis: A Review of Therapeutic Potential

Open Access
Multiple Sclerosis
Review

Advances in the Pharmacological Management of Parkinson’s Disease

Parkinson Disease
Review

Inhibiting CD40 Ligand in Multiple Sclerosis: A Review of Emerging Therapeutic Potential

Open Access
Multiple Sclerosis
Review

The Impacts of the Covid-19 Pandemic on Cerebral Infarction Treatment: Challenges and Opportunities

COVID-19
Review

A Hypoxia-Inflammation Cycle and Multiple Sclerosis: Mechanisms and Therapeutic Implications

Open Access
Multiple Sclerosis
Review

Epstein-Barr Virus as a Therapeutic and Preventive Target in Multiple Sclerosis

Epstein-Barr Virus
Review

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Advances in Alzheimer's

Alzheimer Disease
Independent Medical Education

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:

Lilly

Developed by: Springer Healthcare IME

Learn more

Podcast | Sexual health in older age

Springer Medicine

Vaccine Based Approaches for the Prevention and Treatment of Neurological Disease

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 1/2025

Tau in Multiple Sclerosis: A Review of Therapeutic Potential

Advances in the Pharmacological Management of Parkinson’s Disease

Inhibiting CD40 Ligand in Multiple Sclerosis: A Review of Emerging Therapeutic Potential

The Impacts of the Covid-19 Pandemic on Cerebral Infarction Treatment: Challenges and Opportunities

A Hypoxia-Inflammation Cycle and Multiple Sclerosis: Mechanisms and Therapeutic Implications

Epstein-Barr Virus as a Therapeutic and Preventive Target in Multiple Sclerosis

Keynote series | Spotlight on menopause

Advances in Alzheimer's

Podcast | Sexual health in older age

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content